Specialty chemicals manufacturer Neogen Chemicals Ltd announced on Monday (August 31) that its wholly owned subsidiary Neogen Ionics Ltd will transfer an undertaking to step-down subsidiary Neogen Morita New Materials Ltd for a lump-sum consideration of ₹245 crore. According to reports from CNBC TV18, the transaction will be undertaken on a going-concern basis through a Business Transfer Agreement (BTA), subject to applicable regulatory approvals and completion of conditions precedent. The Board of Directors of both entities approved the Business Transfer Agreement on August 31, 2026, with shareholders of Neogen Ionics Ltd also granting necessary approvals during the same meeting.
The boards of both subsidiaries approved the transaction on Monday, with shareholders of Neogen Ionics Ltd also approving the proposed transfer. As reported by CNBC TV18, the BTA is expected to be executed within a week, while the transaction is likely to be completed on or before March 31, 2027. The consideration of ₹245 crore, after deducting relevant liabilities and including the relevant assets, is to be received on or before March 31, 2027. Given the nil turnover history of Neogen Morita New Materials Ltd, this strategic move aims to consolidate the electrolyte salt manufacturing operations under a single entity.
The undertaking being transferred had a net worth of ₹155.52 crore as of March 31, 2026, according to the filing reported by CNBC TV18. It contributed no revenue during the financial year ended March 31, 2026, and accounted for 19.05% of Neogen Chemicals' consolidated net worth and 57.36% of Neogen Ionics Ltd's consolidated net worth. Neogen Ionics Ltd is an unlisted public limited company incorporated in March 2023 with a turnover of ₹35.97 crore as of March 31, 2026. The divergence between NIL's revenue contribution and its net worth contribution highlights the capital-intensive nature of the electrolyte salt assets, with the transferred assets being primarily fixed or inventory-based investments rather than high-turnover trading books.
As reported by CNBC TV18, the transaction is classified as a related-party transaction between NIL and NML and is exempted under Regulation 23 of the Securities and Exchange Board of India (SEBI) Listing Regulations and Section 188 of the Companies Act, 2013. The company stated that the transaction is part of its strategic initiative to consolidate its Electrolyte Salt (LiPF6) businesses under NML. The undertaking constitutes an undertaking under Section 180 of the Companies Act, 2013, with required approvals obtained. This strategic consolidation aims to centralize specialized manufacturing capabilities within Neogen Morita New Materials Ltd, which was incorporated in July 2025 and is engaged in manufacturing chemicals, including electrolyte salts such as LiPF6 and NaPF6, with nil turnover as of March 31, 2026.
According to CNBC TV18, shares of Neogen Chemicals Ltd ended at ₹2,208.00, down by ₹1.85, or 0.084%, on the BSE following the announcement. The transaction qualifies as a related party transaction between wholly owned subsidiaries and is exempt from specific approval requirements, streamlining the regulatory process. The consolidation strategy positions Neogen Morita New Materials Ltd to handle the specialized electrolyte salt manufacturing operations, potentially improving operational efficiency and cost structures in the coming fiscal years.
